Literature DB >> 22918794

Targeting neuroendocrine tumor: mixing standard options with novel therapies.

Eric Raymond, Chantal Dreyer, Sandrine Faivre.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22918794     DOI： 10.1007/s11523-012-0231-z

Source DB:  PubMed          Journal:  Target Oncol        ISSN： 1776-2596            Impact factor:   4.493


× No keyword cloud information.
  11 in total

Review 1.  Sunitinib in pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Pascal Hammel; Chantal Dreyer; Christian Maatescu; Olivia Hentic; Philippe Ruszniewski; Sandrine Faivre
Journal:  Target Oncol       Date:  2012-06-02       Impact factor: 4.493

2.  ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.

Authors:  Marianne Pavel; Eric Baudin; Anne Couvelard; Eric Krenning; Kjell Öberg; Thomas Steinmüller; Martin Anlauf; Bertram Wiedenmann; Ramon Salazar
Journal:  Neuroendocrinology       Date:  2012-02-15       Impact factor: 4.914

3.  New treatments of pancreatic neuroendocrine tumors: why using them? How to use them?

Authors:  Eric Raymond; Philippe Ruszniewski
Journal:  Target Oncol       Date:  2012-06-05       Impact factor: 4.493

4.  Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.

Authors:  Marianne E Pavel; John D Hainsworth; Eric Baudin; Marc Peeters; Dieter Hörsch; Robert E Winkler; Judith Klimovsky; David Lebwohl; Valentine Jehl; Edward M Wolin; Kjell Öberg; Eric Van Cutsem; James C Yao
Journal:  Lancet       Date:  2011-11-25       Impact factor: 79.321

5.  Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma.

Authors:  C G Moertel; J A Hanley; L A Johnson
Journal:  N Engl J Med       Date:  1980-11-20       Impact factor: 91.245

6.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

7.  Everolimus for advanced pancreatic neuroendocrine tumors.

Authors:  James C Yao; Manisha H Shah; Tetsuhide Ito; Catherine Lombard Bohas; Edward M Wolin; Eric Van Cutsem; Timothy J Hobday; Takuji Okusaka; Jaume Capdevila; Elisabeth G E de Vries; Paola Tomassetti; Marianne E Pavel; Sakina Hoosen; Tomas Haas; Jeremie Lincy; David Lebwohl; Kjell Öberg
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

8.  Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma.

Authors:  C G Moertel; M Lefkopoulo; S Lipsitz; R G Hahn; D Klaassen
Journal:  N Engl J Med       Date:  1992-02-20       Impact factor: 91.245

9.  Sunitinib paves the way for targeted therapies in neuroendocrine tumors.

Authors:  Eric Raymond; Sandrine Faivre; Pascal Hammel; Philippe Ruszniewski
Journal:  Target Oncol       Date:  2009-11-13       Impact factor: 4.493

10.  Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib.

Authors:  Sandrine Faivre; Maxime Ronot; Chantal Dreyer; Camille Serrate; Olivia Hentic; Mohamed Bouattour; Onorina Bruno; Anne Couvelard; Valérie Vilgrain; Eric Raymond
Journal:  Target Oncol       Date:  2012-05-15       Impact factor: 4.493
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.